Hormone receptor-positive HER2-negative advanced breast cancer

Clinical trials for Hormone receptor-positive HER2-negative advanced breast cancer explained in plain language.

Never miss a new study

Get alerted when new Hormone receptor-positive HER2-negative advanced breast cancer trials appear

Sign up with your email to follow new studies for Hormone receptor-positive HER2-negative advanced breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 1 Completed 2 Terminated 1

Can a breast cancer combo be safer for diabetics?

Disease control Not yet recruiting

This trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…

Matched conditions: HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER

Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control

Last updated Sep 18, 2026 00:00 UTC

Hormone receptor-positive HER2-negative advanced breast cancer

Get alerted when new Hormone receptor-positive HER2-negative advanced breast cancer trials appear

Can a breast cancer combo be safer for diabetics?